India's drug standards delay raises worries over reputation, quality

RAJASTHAN, India -- India has given small and midsize drug manufacturers another year to comply with international standards, a move that experts say further dents the reputation of an industry whose products have been linked to deaths across the world.

New Delhi said last month it would delay to the end of 2025 the implementation of a new regulation designed to bring pharmaceutical companies with annual turnovers of under $29 million on par with the World Health Organization's "good manufacturing practices."